ThermoGenesis Holdings, Inc. (THMO)

Market Cap	2.76M
Revenue (ttm)	9.72M
Net Income (ttm)	-14.39M
Shares Out	3.14M
EPS (ttm)	-8.42
PE Ratio	n/a
Forward PE	18.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,881
Open	0.920
Previous Close	0.945
Day's Range	0.920 - 0.920
52-Week Range	0.780 - 6.670
Beta	2.33
Analysts	Strong Buy
Price Target	5.00 (+443.42%)
Earnings Date	Nov 13, 2023

About THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1986
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: THMO

Financial Performance

In 2022, THMO's revenue was $10.48 million, an increase of 12.79% compared to the previous year's $9.29 million. Losses were -$11.27 million, -0.96% less than in 2021.

Analyst Forecast

According to one analyst, the rating for THMO stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target

$5.0

(443.42% upside)

Analyst Consensus: Strong Buy